Clinical use of dexmedetomidine as premedicant in cats undergoing propofol-sevoflurane anaesthesia

The purpose of this report was to evaluate the cardiorespiratory effects and efficacy of dexmedetomidine as a premedicant agent in cats undergoing ovariohysterectomy anaesthetized with propofol-sevoflurane. Cats were randomly divided into two groups of eight animals each. Dexmedetomidine (0.01 mg/kg) or 0.9% saline was administered intravenously (D and S, respectively). After 5 min, propofol was administered intravenously and anaesthesia was maintained with sevoflurane. Heart and respiratory rates, arterial blood pressure, oxygen saturation, rectal temperature and the amount of propofol needed for induction were measured. Premedication with dexmedetomidine reduced the requirement of propofol (6.7+/-3.8 mg/kg), but induced bradycardia, compared with the administration of saline (15.1+/-5.1 mg/kg). Recovery quality was significantly better in D but no significant difference in time to return of swallowing reflex was observed between groups (D=2.5+/-0.5 min; S=3.2+/-1.8 min). In conclusion, dexmedetomidine is a safe and effective agent for premedication in cats undergoing propofol-sevoflurane anaesthesia with minimal adverse effects.     

Assessment of methadone as an anaesthetic premedicant in cats

Ninety cats scheduled to undergo surgical procedures requiring the provision of postoperative analgesia were premedicated with either 0·1, 0·3 or 0·5 mgl/kg of racemic methadone by intramuscular injection. Each cat was assessed on three behavioural criteria before administration and again 20 minutes later. In a further 20 cats a specific assessment was made of the respiratory rate, heart rate and intraoperative minute volume during ovariohysterectomy following premedication with methadone (0·5 mgl/kg intramuscularly). In these cats an assessment of duration of analgesia was attempted. There was no significant change in behavioural scores following premedication with methadone. No cat vomited or became excited. No evidence of serious respiratory depression was found in the 20 cats monitored in detail. Duration of analgesia in cats receiving methadone (0·5 mgl/kg intramuscularly) before ovariohysterectomy varied from 1·5 to over 6·5 hours. Methadone may be used at dose rates of up to 0·5 mg/kg as a premedicant for cats without significant risk of undesirable behavioural changes or serious intraoperative respiratory depression when combined with the anaesthetic protocol described.     

Medetomidine as a premedicant in dogs and its reversal by atipamezole

Medetomidine (10, 20, 40 μg/kg) was used as a premedicant before thiopentone, halothane and nitrous oxide anaesthesia in 60 dogs undergoing a variety of elective surgical and diagnostic procedures at the University of Liverpool Small Animal Hospital. The efficacy of the sedation produced by the three dose groups was evaluated using a sedation scoring system which is presented. Induction of anaesthesia was accomplished using 1–25 per cent thiopentone sodium administered slowly to effect. The mean dose of thiopentone required for intubation following 10 μ-g/kg medetomidine (group 1) was 6–9 mg/kg (SD ± 2–3 mg/kg), following 20 μ-g/kg medetomidine (group 2) was 4–5 mg/kg (SD ± 1–6 mg/kg) and following 40 μg/kg (group 3) was 2–4 mg/kg (SD ± 2–5 mg/kg). Induction of anaesthesia was generally smooth and significant apnoea (greater than 45 seconds) was not noted. Anaesthesia was maintained in all cases using halothane vapourised in a one part oxygen to two parts nitrous oxide mixture, delivered to the patient via a suitable non-breathing circuit (Magill, Bain or T Piece). At the conclusion of the procedure, atipamezole (50, 100, 200 μg/kg) was administered intramuscularly to half of the dogs in each group (10 dogs). Dogs receiving atipamezole recovered rapidly and smoothly to sternal recumbency, group 1 taking 8-5 minutes (SD ± 2–7 minutes), group 2 taking 11-8 minutes (SD ± 3–6 minutes), and group 3 taking 12-6 minutes (sd ± 4–5 minutes). When atipamezole was not administered a dose dependent increase in recumbency time occurred.     

Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog

The effects of premedication with four different intravenous doses of romifidine (20, 40, 80 and 120 (μg/kg body weight) and a saline placebo were compared in a group of 20 adult beagles of both sexes, undergoing anaesthesia with propofol for a clinical dental procedure. Anaesthesia was induced 10 minutes after premedication and maintained by intravenous infusion of propofol for a period of 30 minutes. Romifidine had a marked synergistic effect with propofol and reduced the required induction and infusion doses by more than 60 per cent for a standard level of anaesthesia; the synergistic effect was dose related. Following premedication, propofol produced no significant alteration of respiratory rate, heart rate or rectal temperature. Anaesthesia was found to be more stable following romifidine premedication at all doses studied. The quality of induction was unaltered by the dose of the romifidine. Recovery from anaesthesia was smooth and of a similar quality in all cases. There were no differences in the recovery times between the unpremedicated group and the dogs premedicated with any dose of romifidine studied. There were no adverse effects noted following this anaesthetic regimen. The marked dose-related synergism with propofol induction and infusion anaesthesia is relevant should romifidine be used in the dog in clinical veterinary practice.     

Attitudes of owners regarding tendonectomy and onychectomy in cats

OBJECTIVE: To compare the incidence of behavior problems following tendonectomy or onychectomy in cats, as well as attitudes of owners following these procedures. DESIGN: Nonrandomized clinical trial. ANIMALS: 18 cats that underwent tendonectomy and 39 cats that underwent onychectomy. PROCEDURE: Owners of cats that underwent tendonectomy or onychectomy between February 1993 and May 1998 were contacted by telephone and asked several questions regarding reasons for surgery as well as complications and behavioral changes in cats following surgery. RESULTS: The most common reason for considering tendonectomy or onychectomy was to avoid damage caused by the cat scratching household materials. Avoidance of injury to humans or animals was chosen more often by owners whose cats underwent onychectomy than those that underwent tendonectomy. Tendonectomy was more likely to have been recommended by veterinarians than onychectomy. Significantly more cats that underwent tendonectomy (67%) than onychectomy (44%) returned to normal activity within 3 days after surgery. Significant differences were not detected regarding behavior problems after surgery. CONCLUSIONS AND CLINICAL RELEVANCE: Although tendonectomy and onychectomy involved some medical complications and behavior changes following surgery, owners had positive attitudes regarding both surgeries after the immediate postoperative period. Tendonectomy may be a humane alternative to onychectomy, although owners need to be advised that nail trimming is still necessary in cats after surgery.     

Observations on the use of cyproheptadine hydrochloride as an antipruritic agent in allergic cats.

Cyproheptadine hydrochloride was administered to 20 presumed or proven allergic cats to determine its efficacy in controlling pruritus. Each cat received 2 mg, orally, every 12 h. The pruritus was satisfactorily controlled in 9 cats. Side effects were seen in 8 cats, and included polyphagia, sedation, vocalization, affectionate behavior, and vomiting.     

Current concepts on the use of antimicrobials in cats

This article reviews the general pharmacological properties of antimicrobial drugs used in feline medicine. It focuses on recent advances in pharmacokinetics, providing an update on indications, drug interactions and adverse reactions or toxicity in the cat. Attention is given to the most used groups, such as cephalosporins and fluoroquinolones, reviewing their basic features and clinical uses, and discusses the pharmacokinetic advantages of the newer members of each group. The older groups (penicillins, aminoglycosides, macrolides and tetracyclines) are also considered with regard to their general features and current uses, and any recent reports on adverse reactions in cats are provided.     

Clinical use of yohimbine as an antagonist of xylazine depression of the central nervous system in cats

Antagonizing effects of various doses of yohimbine on a xylazine depression of the cerebroneural system (CNS) were studied in cats. Administration of various doses of yohimbine was investigated with respect to its antagonizing effects on various doses of xylazine. The time of CNS depression induced by commonly recommended doses of xylazine (2-4 mg/kg live weight) was shortened statistically significantly by intramuscular injections of yohimbine at a dose of 3 mg per kg live weight. After this yohimbine dose, the animals recovered consciousness already 10-15 minutes from application, with the complete resumption of reflexes. Preventive administration of the same dose of yohimbine hindered reliably the full development of CNS depression after the two xylazine doses (2 and 4 mg/kg live weight).     

Clinical effectiveness of atipamezole as a medetomidine antagonist in cats

The efficacy of atipamezole to reverse medetomidine induced effects in cats was investigated in a clinical study (n=160) including placebo. The atipamezole doses (intramuscularly) were two, four and six times (2X, 4X and 6X) the preceding medetomidine dose, which was 100 ug/kg body weight intramuscularly. Medetomidine was shown to produce moderate to deep sedation, recumbency and bradycardia in cat. Atipamezole was clearly able to reverse these effects of medetomidine. The median arousal time in the atipamezole dose groups was five minutes and walking time, 10 minutes, compared with more than 30 minutes in the placebo group. Heart rate was increased towards normal by atipamezole in a dose related manner. The clinical evaluation of the ability of atipamezole to reverse the effects of medetomidine was found to be ‘good’ in 82-5, 75 or 65 per cent of cases in dose groups 2X, 4X and 6X, respectively. The effect of atipamezole was evaluated as being ‘too potent’ in 2–5, 5 or 25 per cent of the cases in these respective groups. The incidence of side effects was negligible. In conclusion, atipamezole at the dose of two to four times the preceding dose of medetomidine seems to be an effective medetomidine antagonist for clinical use in cats.     

Disposition and clinical use of bromide in cats

OBJECTIVE: To establish a dosing regimen for potassium bromide and evaluate use of bromide to treat spontaneous seizures in cats. DESIGN: Prospective and retrospective studies. ANIMALS: 7 healthy adult male cats and records of 17 cats with seizures. PROCEDURE: Seven healthy cats were administered potassium bromide (15 mg/kg [6.8 mg/lb], p.o., q 12 h) until steady-state concentrations were reached. Serum samples for pharmacokinetic analysis were obtained weekly until bromide concentrations were not detectable. Clinical data were obtained from records of 17 treated cats. RESULTS: In the prospective study, maximum serum bromide concentration was 1.1 +/- 0.2 mg/mL at 8 weeks. Mean disappearance half-life was 1.6 +/- 0.2 weeks. Steady state was achieved at a mean of 5.3 +/-1.1 weeks. No adverse effects were detected and bromide was well tolerated. In the retrospective study, administration of bromide (n = 4) or bromide and phenobarbital (3) was associated with eradication of seizures in 7 of 15 cats (serum bromide concentration range, 1.0 to 1.6 mg/mL); however, bromide administration was associated with adverse effects in 8 of 16 cats. Coughing developed in 6 of these cats, leading to euthanasia in 1 cat and discontinuation of bromide administration in 2 cats. CONCLUSIONS AND CLINICAL RELEVANCE: Therapeutic concentrations of bromide are attained within 2 weeks in cats that receive 30 mg/kg/d (13.6 mg/lb/d) orally. Although somewhat effective in seizure control, the incidence of adverse effects may not warrant routine use of bromide for control of seizures in cats.